Latest Announcements

Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray in Singapore, Hong Kong and Vietnam

20 Jan 2022 | Read More

Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe

17 Jan 2022 | Read More

Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris™ Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age and

14 Jan 2022 | Read More

Glenmark Pharmaceuticals makes it to the prestigious Dow Jones Sustainability Emerging Markets Index for the fourth consecutive year

16 Nov 2021 | Read More

Newspaper Publication of Q2 FY 2021-22 Result

15 Nov 2021 | Read More

Glenmark Pharma reports revenue growth of 6.6% and PAT growth of 10.1% YoY for Q2 FY 2021-22

12 Nov 2021 | Read More

Glenmark's MDA Q2 FY 2021 - 22

12 Nov 2021 | Read More

Glenmark's Q2 FY 2021-22 Results

12 Nov 2021 | Read More

Q2 FY22 Earnings Call Invitation - November 15, 2021

3 Nov 2021 | Read More

Board Meeting Intimation - 12 November, 2021

1 Nov 2021 | Read More

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin + Metformin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

26 Oct 2021 | Read More

Glenmark launches Tavulus® for COPD treatment in Spain, becoming one of the first companies to launch a bioequivalent version of the dry powder inhaler

11 Oct 2021 | Read More

Transcript of the 43rd AGM

6 Oct 2021 | Read More

Proceedings and Scrutinizer's Report of the 43rd AGM

6 Oct 2021 | Read More

Chairman's Speech at 43rd AGM

6 Oct 2021 | Read More

Glenmark receives marketing approval for Ryaltris®, an innovative combination nasal spray, in 13 countries across the EU and UK

30 Sep 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Foam, 1%

21 Sep 2021 | Read More

Glenmark concludes post marketing surveillance (PMS) study on Favipiravir (FabiFlu®) in 1000+ COVID-19 patients, findings reinforce the drug’s safety and efficacy in real world settings

15 Sep 2021 | Read More

43rd AGM Notice - Newspaper Advertisement

8 Sep 2021 | Read More

Glenmark AGM Notice 2021

27 Aug 2021 | Read More

Newspaper Publication of Q1 FY 2021-22 Result

16 Aug 2021 | Read More

Glenmark Pharma reports revenue growth of 26% and PAT growth of 21% YoY for Q1 FY 2021-22

13 Aug 2021 | Read More

Glenmark’s MDA Q1 FY 2021 – 22

13 Aug 2021 | Read More

Glenmark’s Q1 FY 2021-22 Results

13 Aug 2022 | Read More

Q1 FY22 Earnings Call Invitation – August 16, 2021

9 Aug 2021 | Read More

Board Meeting Intimation – 13th August, 2021

6 Aug 2021 | Read More

Glenmark inks agreement with Canadian biotech SaNOtize to commercialize Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets

2 Aug 2021 | Read More

Newspaper notice to shareholders for transfer of shares to IEPF

28 Jun 2021 | Read More

SCRIP_27 May 2021: Favipiravir Adds Near-Equivalent Of AZ India To Glenmark's Sales

28 Jun 2021 | Read More

Glenmark receives ANDA tentative approval for Nintedanib Capsules, 100 mg and 150 mg

25 Jun 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials

23 Jun 2021 | Read More

Glenmark launches Tiogiva®, becoming one of the first companies in the UK to launch a bioequivalent version of Tiotropium Bromide dry powder inhaler

15 Jun 2021 | Read More

Glenmark releases interim data from PMS Study on Favipiravir

8 Jun 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Theophylline Extended-Release Tablets, 300 mg and 450 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity on the 450 mg

4 Jun 2021 | Read More

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

1 Jun 2021 | Read More

Newspaper Publication of Q4 FY 2020-21 Result

31 May 2021 | Read More

Glenmark’s consolidated revenues grow 2.8% to Rs. 1,09,439 Mn in FY21

28 May 2021 | Read More

Glenmark’s MDA Q4 FY 2020 – 21

28 May 2021 | Read More

Glenmark’s Q4 FY 2020-21 Results

28 May 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe

24 May 2021 | Read More

Newspaper Advertisement for the Board Meeting on 28th May, 2021

20 May 2021 | Read More

Q4 FY21 Earnings Call Invitation – May 31, 2021

20 May 2021 | Read More

Board Meeting Intimation – 28th May, 2021

19 May 2021 | Read More

Glenmark launches Ryaltris®-AZ at an affordable price in India

3 May 2021 | Read More

Glenmark Pharmaceuticals Limited has entered into an agreement to become a partner in ABCD Technologies LLP (to be renamed as Indo Health Services LLP)

30 Apr 2021 | Read More

Glenmark’s Ryaltris ® nasal spray now approved in Europe for the first line treatment of allergic rhinitis in patients over 12 years of age

26 Apr 2021 | Read More

Proposed Initial Public Offering (“IPO”) of Glenmark Life Sciences Limited‐ Filing of draft red herring prospectus

17 Apr 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity.

24 Mar 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 60 mg, 90 mg, and 120 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity

23 Mar 2021 | Read More

Glenmark and Bausch Health join together to commercialize RYALTRIS ™ nasal spray in Canada

22 Mar 2021 | Read More

Glenmark signs on Rohit Sharma as brand ambassador of Candid Powder

5 Mar 2021 | Read More

Glenmark receives ‘India Pharma Innovation of the Year’ Award from the Govt. of India

25 Feb 2021 | Read More

Glenmark’s Ryaltris®- innovative single nasal spray, ready to market in Russia

22 Feb 2021 | Read More

Newspaper Publication of Q3 FY 2020-21 Result

16 Feb 2021 | Read More

Glenmark launches SUTIB (Sunitinib) – priced 96% lower than the innovator brand. Reduces the risk of kidney cancer progression by 58%

16 Feb 2021 | Read More

Glenmark’s consolidated sales rises by 3.88% to Rs. 27,605.07 Mn. in Q3 FY 2020-21

12 Feb 2021 | Read More

Glenmark’s MDA Q3 FY 2020 – 21

12 Feb 2021 | Read More

Glenmark’s Q3 FY 2020-21 Results

12 Feb 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Phosphate Gel USP, 1%

11 Feb 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg

3 Feb 2021 | Read More

Newspaper Advertisement for the Board Meeting on 12th February, 2021

2 Feb 2021 | Read More

Board Meeting Intimation – 12th February, 2021

1 Feb 2021 | Read More

Q3 FY21 Earnings Call Invitation – February 15, 2021

1 Feb 2021 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Amphetamine Sulfate Tablets USP, 5 mg and 10 mg

28 Jan 2021 | Read More

Glenmark Pharmaceuticals receives ANDA final approval for Tadalafil Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg; and receives ANDA tentative approvals for Gabapentin Enacarbil Extended-Release Tablets, 300 mg and 600 mg and Apremilast Tablets, 10 mg, 20 mg and

31 Dec 2020 | Read More

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

29 Dec 2020 | Read More

Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray across numerous markets throughout Europe.

23 Dec 2020 | Read More

Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg

21 Dec 2020 | Read More

Glenmark Pharmaceuticals receives ANDA tentative approval for Axitinib Tablets,1 mg and 5 mg

1 Dec 2020 | Read More

Glenmark to divest select Anti-Allergy brands to Dr Reddy’s in Russia, Ukraine, Kazakhstan and Uzbekistan in anticipation of its ‘Ryaltris’ Launch

28 Nov 2020 | Read More

Credit Rating by S&P Global Ratings

25 Nov 2020 | Read More

Recently published data on Favipiravir as treatment for mild to moderate COVID-19 demonstrates significant improvement in time to clinical cure

23 Nov 2020 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg

11 Nov 2020 | Read More

Newspaper Publication of Q2 FY 2020-21 Result

9 Nov 2020 | Read More

Glenmark’s consolidated revenue increased by 4.88 % to Rs. 29,524.79 mn for Q2 FY 2020-21

6 Nov 2020 | Read More

Glenmark’s MDA Q2 FY 2020 – 21

6 Nov 2020 | Read More

Glenmark’s Q2 FY 2020-21 Results

6 Nov 2020 | Read More

Board Meeting Newspaper Advertisement – November 6, 2020

29 Oct 2020 | Read More

Q2 FY21 Earnings Call Invitation – November 9, 2020

28 Oct 2020 | Read More

Board Meeting Intimation – 6th November, 2020

27 Oct 2020 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg

19 Oct 2020 | Read More

Glenmark introduces NINDANIB (Nintedanib) for the treatment of Pulmonary Fibrosis in India

14 Oct 2020 | Read More

Glenmark announces results of its “FAITH” combination trial

14 Oct 2020 | Read More

Transcript of the 42nd AGM

5 Oct 2020 | Read More

Proceedings and Scrutinizer's Report of the 42nd AGM

30 Sep 2020 | Read More

Chairman’s Speech at the 42nd AGM

30 Sep 2020 | Read More

42nd AGM Notice – Newspaper Advertisement

7 Sep 2020 | Read More

Newspaper Advertisement of 42nd Annual General Meeting

4 Sep 2020 | Read More

Glenmark AGM Notice 2020

4 Sep 2020 | Read More

Newspaper Publication of Q1 FY 2020-21 Result

17 Aug 2020 | Read More

Glenmark’s consolidated revenue grew by 0.94 % at Rs. 23,447.87 Mn. for Q1 FY 2020-21

14 Aug 2020 | Read More

Glenmark’s MDA Q1 FY 2020 – 21

14 Aug 2020 | Read More

Glenmark’s Q1 FY 2020-21 Results

14 Aug 2020 | Read More

Board Meeting Newspaper Advertisement – 14th August, 2020

7 Aug 2020 | Read More

Board Meeting Intimation – 14th August, 2020

6 Aug 2020 | Read More

Q1 FY21 Earnings Call Invitation – August 17, 2020

6 Aug 2020 | Read More

Credit Rating by Fitch Ratings

13 Jul 2020 | Read More

Notice to Shareholders for transfer of shares to IEPF

2 Jul 2020 | Read More

Glenmark’s MDA Q4 FY 2019 – 20

26 Jun 2020 | Read More

Glenmark’s Q4 FY 2019-20 Results

26 Jun 2020 | Read More

Glenmark’s consolidated revenue rises 7.96% to Rs. 27,674.89 Mn. for Q4 FY2019-20

26 Jun 2020 | Read More

Board Meeting Intimation – 26th June, 2020

19 Jun 2020 | Read More

Board Meeting Intimation – 26th June, 2020

17 Jun 2020 | Read More

Q4 FY20 Earnings Call Invitation – June 29, 2020

17 Jun 2020 | Read More

Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India

12 May 2020 | Read More

Glenmark introduces 3-in-1 inhaler therapy for COPD in India, promising reduction in risk of severe attacks and improvement in lung function

11 May 2020 | Read More

Glenmark receives approval from the regulator (DCGI) to conduct Clinical Trials in India on Favipiravir Antiviral tablets for COVID-19 patients

30 Apr 2020 | Read More

Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin and Saxagliptin Tablets, 10 mg/5 mg

29 Apr 2020 | Read More

Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin Tablets, 5 mg and 10 mg

23 Mar 2020 | Read More

Glenmark divests VWash, a female intimate hygiene wash, to Hindustan Unilever

23 Mar 2020 | Read More

Glenmark Pharmaceuticals and Hikma enter into an Exclusive Licensing Agreement for commercializing Ryaltris™ Seasonal Allergic Rhinitis Nasal Spray in the US

27 Feb 2020 | Read More

Newspaper Publication of Q3 FY 2019-20 Result

17 Feb 2020 | Read More

Glenmark’s consolidated revenue rises by 7.07% to Rs. 27,355.61 Mn. in Q3 FY 2019-20

14 Feb 2020 | Read More

Glenmark’s MDA Q3 FY 2019 – 20

14 Feb 2020 | Read More

Glenmark’s Q3 FY 2019-20 Results

14 Feb 2020 | Read More

Q3 FY20 Earnings Call Invitation – February 17, 2020

4 Feb 2020 | Read More

BM Notice Newspaper Publication – 14th February, 2020

3 Feb 2020 | Read More

Notice of Board Meeting - 31st January, 2020

31 Jan 2020 | Read More

Glenmark Pharmaceuticals announces product approval for Ryaltris(R) in Australia

20 Dec 2019 | Read More

Certificate of Compliance issued by the European regulator, SUKL, Czech Republic for Glenmark’s Baddi manufacturing facility

16 Dec 2019 | Read More

Newspaper Publication of Q2 FY 2019-20

19 Nov 2019 | Read More

Glenmark’s consolidated revenue rises 9.05% to Rs. 28,150.4 Mn. in Q2 FY 2019-20

14 Nov 2019 | Read More

Glenmark’s MDA Q2 FY 2019 – 20

14 Nov 2019 | Read More

Glenmark’s Q2 FY 2019-20 Results

14 Nov 2019 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Adapalene and Benzoyl Peroxide Gel, 0.1%|2.5%

11 Nov 2019 | Read More

Q2 FY20 Earnings Concall Invitation - November 15, 2019

7 Nov 2019 | Read More

BM Notice Newspaper Publication – 14th November, 2019

6 Nov 2019 | Read More

Notice of Board Meeting - 14th November, 2019

5 Nov 2019 | Read More

Proceedings and Scrutinizer's Report of the 41st AGM

28 Sep 2020 | Read More

Newspaper Publication of Annual General Meeting Notice

5 Sep 2019 | Read More

Glenmark AGM Notice 2019

3 Sep 2019 | Read More

AGM Intimation to the Exchange

25 Aug 2019 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)

23 Aug 2019 | Read More

Glenmark’s consolidated revenue at Rs. 23,228.79 Mn. for Q1 FY 2019 – 20

13 Aug 2019 | Read More

Glenmark’s MDA Q1 FY 2019 – 20

13 Aug 2019 | Read More

Glenmark’s Q1 FY 2019-20 Results

13 Aug 2019 | Read More

Glenmark Q1 FY 2019 – 20 Results Earnings Call

5 Aug 2019 | Read More

BM Notice Newspaper Publication – 13th August, 2019

1 Aug 2019 | Read More

Notice of Board Meeting - 13th August, 2019

31 Jul 2019 | Read More

Credit Rating by Fitch Ratings

11 Jul 2019 | Read More

Newspaper Publication - Notice to Shareholder for transfer of shares to IEPF

26 Jun 2019 | Read More

FDA Issues Complete Response Letter for Ryaltris™ (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg])

22 Jun 2019 | Read More

Newspaper Publication of Q4 Results

31 May 2019 | Read More

Glenmark’s consolidated revenue rises 12.44% to Rs. 25,634.74 Mn. for Q4 FY 2018-19

29 May 2019 | Read More

Glenmark’s MDA Q4 FY 2018 – 19

29 May 2019 | Read More

Glenmark’s Q4 FY 2018-19 Results

29 May 2019 | Read More

BM Notice Newspaper Publication – 29th May, 2019

22 May 2019 | Read More

Glenmark Q4 FY 2018 - 19 Results Earnings Call

21 May 2019 | Read More

Board Meeting Intimation – 29th May, 2019

14 May 2019 | Read More

Newspaper Publication of Q3 Results

18 Feb 2019 | Read More

Glenmark’s consolidated revenue rises 15.95% to Rs. 25,550.45 Mn. in Q3 FY 2018 – 19

14 Feb 2019 | Read More

Glenmark’s MDA Q3 FY 2018 – 19

14 Feb 2019 | Read More

Glenmark’s Q3 FY 2018-19 Results

14 Feb 2019 | Read More

BM Newspaper Publication – 14th February, 2019

4 Feb 2019 | Read More

Glenmark Q3 FY 2018 - 19 Results Earnings Call

4 Feb 2019 | Read More

Board Meeting Intimation – 14th February, 2019

1 Feb 2019 | Read More

J P Morgan Healthcare Conference 2019 I Presentation

8 Jan 2019 | Read More

Newspaper Publication of Q2 Results

23 Nov 2018 | Read More

Glenmark’s consolidated revenue rises 14.39% to Rs. 25,813.32 Mn. in Q2 FY 2018 – 19

13 Nov 2018 | Read More

Glenmark’s MDA Q2 FY 2018 – 19

13 Nov 2018 | Read More

Glenmark’s Q2 FY 2018-19 Results

13 Nov 2018 | Read More

BM Newspaper Publication

5 Nov 2018 | Read More

Board Meeting Notice November 13, 2018

2 Nov 2018 | Read More

Announcement of Results of the Repurchase

3 Oct 2018 | Read More

Newspaper Publication of Annual General Meeting Notice

28 Sep 2018 | Read More

AGM Intimation to the exchange

21 Aug 2018 | Read More

Newspaper Publication of Q1 Results

19 Aug 2018 | Read More

Glenmark’s consolidated revenue at Rs. 21,656.17 Mn. for Q1 FY 2018 – 19

10 Aug 2018 | Read More

Glenmark’s Q1 FY 2018-19 Results

10 Aug 2018 | Read More

Glenmark’s MDA Q1 FY 2018 – 19

10 Aug 2018 | Read More

Q1 FY19 Earnings Concall Invitation - Aug 13, 2018

3 Aug 2018 | Read More

Glenmark BM Notice Navshakti

31 Jul 2018 | Read More

Glenmark BM Notice FPJ

31 Jul 2018 | Read More

IEPF – Notice to Shareholders

29 Jun 2018 | Read More

Newspaper Publication of Q4/Annual Results - Loksatta

6 Jun 2018 | Read More

Newspaper Publication of Q4/Annual Results

5 Jun 2018 | Read More

Glenmark’s consolidated revenue at Rs. 22,798.16 Mn. for Q4 FY 2017 – 18

29 May 2018 | Read More

Glenmark’s MDA Q4 FY 18

29 May 2018 | Read More

Glenmark’s Q4 FY18 Results

29 May 2018 | Read More

Q4 Earnings Concall Invitation

28 May 2018 | Read More

Glenmark BM Notice Navshakti

17 May 2018 | Read More

Glenmark BM Notice FPJ

17 May 2018 | Read More

Newspaper Publication of Q3 Results

9 Feb 2018 | Read More

AGM Notice Announcement

8 Sep 2017 | Read More

Board Meeting Notice July 27, 2017

14 Jul 2017 | Read More

Glenmark FPJ Page 10

14 Jul 2017 | Read More

Glenmark Navshakti Page 8

14 Jul 2017 | Read More

Glenmark Pharmaceuticals Receives Tentative ANDA Approval For Solifenacin Succinate Tablets, 5 mg and 10 mg

22 Jun 2017 | Read More

Glenmark's consolidated revenue increased by 6.52% to Rs. 24,571.83 Mn for Q4 FY 2016 -- 17

11 May 2017 | Read More

Q4 FY 2017 Results sheet & Statement of Assets and Liabilities

11 May 2017 | Read More

Q4 FY 2017 Management Discussions and Analysis

11 May 2017 | Read More

Q4 Earnings Concall Invitation May 12, 2017

8 May 2017 | Read More

The Free Press Journal

5 May 2017 | Read More

Navshakti

5 May 2017 | Read More

Intimation regarding NSE board meeting

3 May 2017 | Read More

Statement on Form 483 at the Ankleshwar API plant

20 Feb 2017 | Read More

Glenmark’s Q3 FY 17 results

2 Feb 2017 | Read More

Glenmark’s MDA Q3 FY 17

2 Feb 2017 | Read More

Glenmark’s consolidated revenue increases by 42.55 % to Rs. 25,350.08 Mn for Q3 FY 2016 – 17

2 Feb 2017 | Read More

J P Morgan Healthcare Conference – presentation

30 Jan 2017 | Read More

Intimation regarding board meeting

17 Jan 2017 | Read More

Statement of Investor Complaints for Q3 (F. Y. 2016-17)

11 Jan 2016 | Read More

Webcast of analyst and investor meet 2016

29 Dec 2016 | Read More

Strategic Blueprint for the Next Decade – Investor presentation

19 Dec 2016 | Read More

Strategic Blueprint for the Next Decade – Media presentation

19 Dec 2016 | Read More

Glenmark's Q2 FY17 Result Balance Sheet

2 Nov 2016 | Read More

Glenmark's MDA Q2 FY 2017

2 Nov 2016 | Read More

Glenmark’s consolidated revenue increases by 16.48% to Rs. 22241.09 Mn for Q2 FY 2016 – 17